San Francisco biotech developing drugs that activate iNKT immune cells to clear senescent cells from the body.
Utrecht spinout developing FOXO4-derived senolytic peptides to selectively destroy senescent cells in cancer and chronic disease.
Including Funding rounds + valuations, Founders + executives, Products + tech stack, Headcount + HQ, Status timeline, and Roster connections.
Already subscribed? Sign in →